Diabetes Care, Vol 23, Issue 12 1816-1822, Copyright © 2000 by American Diabetes Association

ARTICLES

Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance

M Buysschaert, AS Dramais, PE Wallemacq and MP Hermans
Service d'Endocrinologie et Nutrition, Cliniques Universitaires St. Luc, Universite Catholique de Louvain, Brussels, Belgium. buysschaert@diab.ucl.ac.be

OBJECTIVE: The aim of this study was to determine the distribution of plasma total homocysteine (tHcy) concentrations in type 2 diabetic patients and to assess whether high tHcy values were related to chronic complications (particularly macroangiopathy and nephropathy) and/or the degree of insulin resistance. RESEARCH DESIGN AND METHODS: Fasting tHcy levels were measured in 122 type 2 diabetic patients in whom the presence of chronic complications (e.g., macroangiopathy, microalbuminuria, macroproteinuria, decreased creatinine clearance, hypertension, retinopathy, and neuropathy) was recorded alongside an assessment of insulin resistance by the homeostasis model assessment (HOMA). RESULTS: We found that 31% of the cohort (group 1) had raised tHcy (mean +/- 1 SD) values (20.8 +/- 5.1 micromol/l), whereas 69% (group 2) had normal values (10.2 +/- 2.0 micromol/l). The prevalence of macroangiopathy was higher in group 1 than in group 2 subjects (70 vs. 42%, P < 0.01); the prevalence of coronary artery disease was particularly higher in group 1 (46 vs. 21%, P < 0.02). The prevalence of impaired renal function, evidenced by decreased creatinine clearance, was higher in group 1 (32 vs. 10%, P < 0.005). Other clinical and biological characteristics of both groups were comparable, although group 1 had lower levels of folic acid than group 2 (5.2 +/- 2.9 vs. 7.0 +/- 3.4 ng/ml, P < 0.01). No differences were found for microalbuminuria (33 vs. 31%), retinopathy (45 vs. 42%), or neuropathy (70 vs. 59%) between groups 1 and 2, respectively The degree of insulin resistance was similar in groups 1 and 2 (46 +/- 21 and 42 +/- 20% of HOMA-insulin sensitivity) as was the assessment of beta-cell function (63 +/- 28 and 65 +/- 46%, respectively). No differences in tHcy levels were found between subjects receiving metformin and those not receiving metformin. In contrast, the plasma tHcy level was higher in diabetic patients treated with fibrates (P = 0.0016). CONCLUSIONS: Elevated plasma tHcy levels in type 2 diabetes is associated with a higher prevalence of macroangiopathy and nephropathy when assessed from creatinine clearance indexes and is not associated with different degrees of insulin resistance.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				U. Sen, W. E. Rodriguez, N. Tyagi, M. Kumar, S. Kundu, and S. C. Tyagi Ciglitazone, a PPAR{gamma} agonist, ameliorates diabetic nephropathy in part through homocysteine clearance Am J Physiol Endocrinol Metab, November 1, 2008; 295(5): E1205 - E1212. [Abstract] [Full Text] [PDF]

				A. Akalin, O. Alatas, and O. Colak Relation of plasma homocysteine levels to atherosclerotic vascular disease and inflammation markers in type 2 diabetic patients Eur. J. Endocrinol., January 1, 2008; 158(1): 47 - 52. [Abstract] [Full Text] [PDF]

				W. E. Rodriguez, I. G. Joshua, J. C. Falcone, and S. C. Tyagi Pioglitazone prevents cardiac remodeling in high-fat, high-calorie-induced Type 2 diabetes mellitus Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H81 - H87. [Abstract] [Full Text] [PDF]

				S Patterson, P R Flatt, L Brennan, P Newsholme, and N H McClenaghan Detrimental actions of metabolic syndrome risk factor, homocysteine, on pancreatic {beta}-cell glucose metabolism and insulin secretion. J. Endocrinol., May 1, 2006; 189(2): 301 - 310. [Abstract] [Full Text] [PDF]

				P. Tessari, A. Coracina, E. Kiwanuka, M. Vedovato, M. Vettore, A. Valerio, M. Zaramella, and G. Garibotto Effects of Insulin on Methionine and Homocysteine Kinetics in Type 2 Diabetes With Nephropathy Diabetes, October 1, 2005; 54(10): 2968 - 2976. [Abstract] [Full Text] [PDF]

				S. C. Tyagi, W. Rodriguez, A. M. Patel, A. M. Roberts, J. C. Falcone, J. C. Passmore, J. T. Fleming, and I. G. Joshua Hyperhomocysteinemic Diabetic Cardiomyopathy: Oxidative Stress, Remodeling, and Endothelial-Myocyte Uncoupling Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2005; 10(1): 1 - 10. [Abstract] [PDF]

				Y. Aso, K.-i. Okumura, K. Takebayashi, S. Wakabayashi, and T. Inukai Relationships of Plasma Interleukin-18 Concentrations to Hyperhomocysteinemia and Carotid Intimal-Media Wall Thickness in Patients With Type 2 Diabetes Diabetes Care, September 1, 2003; 26(9): 2622 - 2627. [Abstract] [Full Text] [PDF]

				U. Rajala, M. Paivansalo, M. Laakso, O. Pelkonen, P. Koskela, I. Suramo, and S. Keinanen-Kiukaanniemi Lack of association between early atherosclerotic carotid artery wall lesions and serum level of homocysteine The British Journal of Diabetes & Vascular Disease, May 1, 2003; 3(3): 230 - 232. [Abstract] [PDF]

				M.-J. J. Pouwels, M. den Heijer, H. J. Blom, C. J. Tack, and A. R. Hermus Improved Insulin Sensitivity and Metabolic Control in Type 2 Diabetes Does Not Influence Plasma Homocysteine Diabetes Care, May 1, 2003; 26(5): 1637 - 1639. [Full Text] [PDF]

				H. S. Randeva, K. C. Lewandowski, J. Drzewoski, K. Brooke-Wavell, C. O'Callaghan, L. Czupryniak, E. W. Hillhouse, and G. M. Prelevic Exercise Decreases Plasma Total Homocysteine in Overweight Young Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4496 - 4501. [Abstract] [Full Text] [PDF]

				B. Ozmen, D. Ozmen, N. Turgan, S. Habif, I. Mutaf, and O. Bayindir Association Between Homocysteinemia and Renal Function in Patients with Type 2 Diabetes Mellitus Ann. Clin. Lab. Sci., July 1, 2002; 32(3): 279 - 286. [Abstract] [Full Text] [PDF]

				J.-M. Gonzalez-Clemente, R. Deulofeu, J. Mitjavila, G. Galdon, E. Ortega, A. Caixas, G. Gimenez-Perez, and D. Mauricio Plasma Homocysteine Is not Increased in Microalbuminuric Patients With Type 2 Diabetes Without Clinical Cardiovascular Disease Diabetes Care, March 1, 2002; 25(3): 632 - 633. [Full Text] [PDF]

				B. S. O'Connell Select Vitamins and Minerals in the Management of Diabetes Diabetes Spectr, August 1, 2001; 14(3): 133 - 148. [Abstract] [Full Text] [PDF]

				N. N. Chan, T. M.M. Tan, and S. J. Hurel Hyperhomocysteinemia and Macroangiopathy in Type 2 Diabetes Diabetes Care, June 1, 2001; 24(6): 1123 - 1124. [Full Text]

				M. Buysschaert and M.P. Hermans Response to Chan et al.: Hyperhomocysteinemia and Macroangiopathy in Type 2 Diabetes Diabetes Care, June 1, 2001; 24(6): 1124 - 1125. [Full Text]

				C. Pavía, I. Ferrer, C. Valls, R. Artuch, C. Colomé, and M. A. Vilaseca Plasma Homocysteine Levels in Type 1 Diabetic Patients Diabetes Care, May 1, 2001; 24(5): 970 - 971. [Full Text]